Eli Lilly (LLY)
(Delayed Data from NYSE)
$921.49 USD
+6.45 (0.70%)
Updated Sep 20, 2024 04:02 PM ET
After-Market: $920.77 -0.72 (-0.08%) 7:58 PM ET
1-Strong Buy of 5 1
F Value F Growth D Momentum F VGM
Brokerage Reports
Eli Lilly and Company [LLY]
Reports for Purchase
Showing records 401 - 420 ( 439 total )
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Specialty Pharmaceuticals Short Interest Analysis
Provider: AURIGA USA
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Focus now to be on progression of R&D pipeline & several initial product data releases...
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Fourth Quarter Results Felt the Impact of the Zyprexa Patent Expiration.
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Raising our CY11 & CY12 estimates in view of strong performance in Q3 CY11........
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Third Quarter Revenue Increased 9% but Heavy Spending Led to Lower Earnings
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Raising our CY11 estimates in view of strong performance in Q2 CY11, though concern remains
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Positive volume Growth with Favorable Currency Trends
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Delays and setbacks on R&D front add further to existing concerns over earnings growth & pipeline productivity.
Provider: FIRST GLOBAL
Analyst: THOMAS K